Vicor Corporation (VICR) fell roughly 19.8% over the last 30 days, from $226.48 on August 4, 2026 to $181.59 on September 2, 2026. The decline extends a broader three-month pullback, with shares down roughly 45% since early June after peaking at a 52-week high of $382.65 on June 30, 2026.

CRL shares climbed roughly 24.6% over the trailing 30 days, rising from about $234 to approximately $292. The advance was driven by stronger-than-expected second-quarter 2026 results and raised full-year guidance.

Halozyme Therapeutics (HALO) rose roughly 31.8% over the last 30 days, climbing from about $83.23 to $109.66. The move was driven primarily by record second-quarter 2026 results, raised full-year guidance, and accelerated share repurchases.

Vipshop Holdings (VIPS) declined roughly 16.3% over the past 30 days, falling from about $15.55 to near $13.03 per ADS. The slide followed second-quarter 2026 results that showed lower revenue, weaker customer activity, and a sharp drop in adjusted profit.

Applied Optoelectronics (AAOI) shares declined about 21.7% over the last 30 days, from $131.63 on August 4, 2026 to $103.13 on September 2, 2026. A record second-quarter report — revenue of $191.92 million, up 86.4% year over year — initially lifted the stock before financing concerns reversed the move.

OR shares have climbed roughly 20% over the past 30 days, rising from about $30.76 to $36.81. The rebound follows a steep mid-year selloff in precious metals equities, as firmer gold prices restored investor confidence.

AAON shares declined approximately 21.9% over the past 30 days, falling from a closing price of $95.55 on August 4, 2026, to $74.62 on September 2, 2026. The pullback extends a broader correction from a 52-week high near $150.46 reached in early June 2026, leaving the stock down roughly 49.7% over the trailing quarter.

Eldorado Gold shares rose about 35.5% over the last 30 days, from $31.82 on August 4 to roughly $43.13 at the most recent close. The advance coincided with a firm gold-price backdrop, a second-quarter earnings-per-share beat, and an analyst upgrade to Outperformer with a $54 price target.

Cognex shares declined roughly 16% over the past 30 days, falling from a closing price near $71.52 to about $59.94. The pullback followed a strong run-up into second-quarter 2026 earnings and largely reflects post-earnings profit-taking after record results.

Middleby shares declined roughly 19% over the last 30 days, falling from a closing price near $138.78 on August 4, 2026, to about $112.44 as of early September. The pullback was driven primarily by second-quarter 2026 results and forward guidance that came in below analyst expectations following the company's portfolio transformation.

Primoris Services (PRIM) shares declined roughly 18% over the last 30 days, falling from about $90.85 to approximately $74.32. The pullback was driven primarily by weak second-quarter 2026 results, including a net loss, compressed margins, and an Energy segment that swung to a gross loss.

ASTS surged +12.42% to $62.73 during Wednesday's regular session, up from a prior close of $55.80. The rally was driven by Berenberg initiating coverage with a Buy rating and a $92 price target, implying roughly +65% upside.

VIOT shares surged roughly +85.57% during Tuesday's regular session, jumping from a $0.9693 prior close to about $1.80 on massive volume. The rally follows renewed focus on overseas momentum: North American Amazon business posted triple-digit H1 growth, with the flagship V6 Pro ranking top-8 in its category during Prime Day.

PLTR fell roughly -6% during Wednesday's regular session, sliding from a prior close of $179.92 to about $169. The primary catalyst was Google DeepMind's launch of Gemini 3.8 Flash Cyber and its "Fairwind" program, a direct push into Palantir's core government/defense AI market.

The selected price target is $10 per share , roughly a 110% gain from recent trading near $4.73 and below the stock's 52-week high of $12.99. Wall Street is notably bullish: the consensus analyst price target is $16 , with individual targets ranging from $13 to $20.

NTHI is up +5.92% during regular-session trading, climbing to roughly $5.01 from a $4.73 prior close. The gain follows a -4.25% pullback on Sept 1, reflecting sustained high volatility in this micro-cap clinical-stage biotech.

GPRO is up +39.02% today, trading near $1.71 during the regular session, extending a multi-day surge that has more than doubled shares off last week's ~$0.60 low. Primary driver: continued reaction to the definitive merger with private photonics firm Starman Optical, a pivot into AI data-center optics and defense that repays ~$92M of debt and pays shareholders $1.14/share plus a ~10% stake in the combined company.

BIAF is up +63.73% intraday to about $10.79, extending the prior session's +44.52% surge; the move occurred during regular market hours. Primary catalyst: the company announced plans to expand its CyPath Lung test into post-treatment surveillance of lung cancer survivors, broadening its commercial use beyond initial screening.

CRDO dropped about -18.65% in regular trading, sliding from a $206.63 prior close to roughly $168. The move extends a post-earnings selloff after fiscal Q1 results (revenue $479M, +115% YoY; EPS $1.20) beat estimates but GAAP gross margin fell to 64.5%, with Q2 guidance seen as thinner than prior quarters.

HTZ traded up +6.7% to about $2.39 during regular market hours versus the prior session's $2.24 close. The primary catalyst was a newly announced partnership with Uber to operate autonomous robotaxis and human-driven fleet operations.